Applied DNA Sciences Inc.
| NASDAQ: APDN |
| Healthcare / Medical Diagnostics & Research / USA |
| 0.8668 | -0.0407 | -4.48% | Vol 78.98K | 1Y Perf -87.05% |
| Jun 27th, 2022 15:59 DELAYED |
| BID | 0.8500 | ASK | 0.9630 | ||
| Open | 0.9300 | Previous Close | 0.9075 | ||
| Pre-Market | - | After-Market | 0.93 | ||
| - - | 0.06 7.12% |
| Target Price | 11.33 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 1.21K | Finscreener Ranking | ★★★★+ 57.85 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 47.78 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★+ 49.42 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | -0.32 | Earnings Rating | Strong Sell | |
| Market Cap | 7.14M | Earnings Date | 11th Aug 2022 | |
| Alpha | -0.04 | Standard Deviation | 0.28 | |
| Beta | 1.11 |
Today's Price Range 0.86570.9414 | 52W Range 0.89008.10 | 5 Year PE Ratio Range -2.20-1.90 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -8.37% | ||
| 1 Month | -24.38% | ||
| 3 Months | -60.71% | ||
| 6 Months | -80.93% | ||
| 1 Year | -87.05% | ||
| 3 Years | -95.95% | ||
| 5 Years | -97.92% | ||
| 10 Years | -99.24% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -158.22 | |||
ROE last 12 Months | -115.32 | |||
ROA (5Y Avg) | -41.85 | |||
ROA last 12 Months | -86.86 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -110.76 | |||
Return on invested Capital Q | -23.37 | |||
Return on invested Capital Y | -169.75 | |||
Assets Turnover | 1.20 | |||
Receivables Turnover | 10.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.50 | ||||
| 1.07 | ||||
| 0.54 | ||||
| - | ||||
| -0.70 | ||||
| -1.30 | ||||
| 1.07 | ||||
| 0.93 | ||||
| 4.76M | ||||
| Forward PE | -1.47 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.50 | ||||
| 3.10 | ||||
| 0.03 | ||||
| 0.15 | ||||
| -2 770.20 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 37.80 | ||||
| -90.50 | ||||
| -82.60 | ||||
| -312.60 | ||||
| -95.11 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 15.05M | ||||
| 1.83 | ||||
| 36.64 | ||||
| 14.26 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2022 | -0.30 | -0.28 | 6.67 |
| Q01 2022 | -0.19 | -0.63 | -231.58 |
| Q04 2021 | -0.32 | -0.49 | -53.12 |
| Q03 2021 | -0.24 | -0.46 | -91.67 |
| Q02 2021 | -0.18 | -0.33 | -83.33 |
| Q01 2021 | -0.55 | -0.62 | -12.73 |
| Q04 2020 | -0.59 | -0.82 | -38.98 |
| Q03 2020 | -0.62 | -0.72 | -16.13 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -0.31 | -29.17 | Negative |
| 9/2022 QR | -0.25 | -13.64 | Negative |
| 9/2022 FY | -1.42 | -7.58 | Negative |
| 9/2023 FY | -0.71 | 5.33 | Positive |
| Next Report Date | 11th Aug 2022 |
| Estimated EPS Next Report | -0.31 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 78.98K |
| Shares Outstanding | 8.23K |
| Shares Float | 8.06M |
| Trades Count | 355 |
| Dollar Volume | 71.30K |
| Avg. Volume | 74.54K |
| Avg. Weekly Volume | 93.10K |
| Avg. Monthly Volume | 76.82K |
| Avg. Quarterly Volume | 53.70K |
Applied DNA Sciences Inc. (NASDAQ: APDN) stock closed at 0.9075 per share at the end of the most recent trading day (a -5.47% change compared to the prior day closing price) with a volume of 92.89K shares and market capitalization of 7.14M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 61 people. Applied DNA Sciences Inc. CEO is James A. Hayward.
The one-year performance of Applied DNA Sciences Inc. stock is -87.05%, while year-to-date (YTD) performance is -77.43%. APDN stock has a five-year performance of -97.92%. Its 52-week range is between 0.89 and 8.1, which gives APDN stock a 52-week price range ratio of -0.32%
Applied DNA Sciences Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 1.07, a price-to-sale (PS) ratio of 0.54, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -86.86%, a ROC of -110.76% and a ROE of -115.32%. The company’s profit margin is -95.11%, its EBITDA margin is -82.60%, and its revenue ttm is $15.05 Million , which makes it $1.83 revenue per share.
Of the last four earnings reports from Applied DNA Sciences Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.31 for the next earnings report. Applied DNA Sciences Inc.’s next earnings report date is 11th Aug 2022.
The consensus rating of Wall Street analysts for Applied DNA Sciences Inc. is Strong Buy (1), with a target price of $11.33, which is +1 207.11% compared to the current price. The earnings rating for Applied DNA Sciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Applied DNA Sciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Applied DNA Sciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.72, ATR14 : 0.12, CCI20 : -113.31, Chaikin Money Flow : -0.38, MACD : -0.12, Money Flow Index : 50.59, ROC : -17.50, RSI : 25.97, STOCH (14,3) : 3.65, STOCH RSI : 0.00, UO : 26.62, Williams %R : -96.35), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Applied DNA Sciences Inc. in the last 12-months were:
Applied DNA Sciences Inc.
Applied DNA Sciences Inc is a provider of DNA-based supply chain, anti-counterfeiting, and anti-theft technology. The company provides its products and services under the brand of SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, digitalDNA, SigNify and Beacon. It serves clients in various industries including government/military, security and asset marking, industrial parts, pharmaceuticals, textiles and apparel, and printing and packaging. The company has operational footprints across the United States, Europe, Asia, and others.
CEO: James A. Hayward
Telephone: +1 631 840-8800
Address: 50 Health Sciences Drive, Stony Brook 11790, NY, US
Number of employees: 61
